Research Article

Can Apigenin Be an Effective Therapeutic Agent Against Experimental Renal Ischemia-Reperfusion Injury?

Volume: 12 Number: 2 July 31, 2024
EN TR

Can Apigenin Be an Effective Therapeutic Agent Against Experimental Renal Ischemia-Reperfusion Injury?

Abstract

Aim: This study aims to reveal the effects of two doses of apigenin (API) against renal ischemia-reperfusion injury (R I/R). Material and Methods: For this purpose, 5 and 10 mg/kg doses of API were preferred in our study, and the groups were designed as sham, R I/R, 5 mg/kg API, and 10 mg/kg API groups for the implementation of the experimental protocol. In the R I/R model, 1-hour ischemia and 24-hour reperfusion periods were preferred. Oxidative and inflammatory markers were measured biochemically in samples taken at the end of the experiment. Results: Biochemical results showed that oxidative and inflammatory markers increased significantly in the R I/R group, but antioxidant activities decreased significantly. In the 5 and 10 mg/kg API groups, R I/R damage was alleviated considerably, with these markers approaching the sham group values. Conclusion: As a result, the study's results determined that two different doses of API were effective against R I/R-induced kidney damage.

Keywords

References

  1. 1. Eltzschig HK, Eckle T. Ischemia and reperfusion--from mechanism to translation. Nat Med. 2011;17(11):1391-401.
  2. 2. Lee YM, Lee G, Oh TI, Kim BM, Shim DW, Lee KH, et al. Inhibition of glutamine utilization sensitizes lung cancer cells to apigenin-induced apoptosis resulting from metabolic and oxidative stress. Int J Oncol. 2016;48(1):399-408.
  3. 3. Malek M, Nematbakhsh M. Renal ischemia/reperfusion injury; from pathophysiology to treatment. J Renal Inj Prev. 2015;4(2):20-7.
  4. 4. Sharfuddin AA, Molitoris BA. Pathophysiology of ischemic acute kidney injury. Nat Rev Nephrol. 2011;7(4):189-200.
  5. 5. Shan YG, Chen DQ, Hu B, Xu GT, Li WL, Jin Y, et al. Allicin ameliorates renal ischemia/reperfusion injury via inhibition of oxidative stress and inflammation in rats. Biomed Pharmacother. 2021;142.
  6. 6. Topdagi O, Tanyeli A, Akdemir FNE, Eraslan E, Guler MC, Comakli S. Preventive effects of fraxin on ischemia/reperfusion-induced acute kidney injury in rats. Life Sci. 2020;242:117217.
  7. 7. Alsadat AM, Nikbakht F, Nia HH, Golab F, Khadem Y, Barati M, et al. GSK-3β as a target for apigenin-induced neuroprotection against Aβ 25-35 in a rat model of Alzheimer's disease. Neuropeptides. 2021;90.
  8. 8. Sung B, Chung HY, Kim ND. Role of Apigenin in Cancer Prevention via the Induction of Apoptosis and Autophagy. J Cancer Prev. 2016;21(4):216-26.

Details

Primary Language

English

Subjects

Surgery (Other)

Journal Section

Research Article

Early Pub Date

July 28, 2024

Publication Date

July 31, 2024

Submission Date

May 20, 2024

Acceptance Date

July 20, 2024

Published in Issue

Year 2024 Volume: 12 Number: 2

APA
Topdağı, Ö., Güler, M. C., Eraslan, E., Ekinci Akdemir, F. N., Tanyeli, A., Özbek Şebin, S., & Şebin, E. (2024). Can Apigenin Be an Effective Therapeutic Agent Against Experimental Renal Ischemia-Reperfusion Injury? Pediatric Practice and Research, 12(2), 53-56. https://doi.org/10.21765/pprjournal.1487201
AMA
1.Topdağı Ö, Güler MC, Eraslan E, et al. Can Apigenin Be an Effective Therapeutic Agent Against Experimental Renal Ischemia-Reperfusion Injury? pediatr pract res. 2024;12(2):53-56. doi:10.21765/pprjournal.1487201
Chicago
Topdağı, Ömer, Mustafa Can Güler, Ersen Eraslan, et al. 2024. “Can Apigenin Be an Effective Therapeutic Agent Against Experimental Renal Ischemia-Reperfusion Injury?”. Pediatric Practice and Research 12 (2): 53-56. https://doi.org/10.21765/pprjournal.1487201.
EndNote
Topdağı Ö, Güler MC, Eraslan E, Ekinci Akdemir FN, Tanyeli A, Özbek Şebin S, Şebin E (July 1, 2024) Can Apigenin Be an Effective Therapeutic Agent Against Experimental Renal Ischemia-Reperfusion Injury? Pediatric Practice and Research 12 2 53–56.
IEEE
[1]Ö. Topdağı et al., “Can Apigenin Be an Effective Therapeutic Agent Against Experimental Renal Ischemia-Reperfusion Injury?”, pediatr pract res, vol. 12, no. 2, pp. 53–56, July 2024, doi: 10.21765/pprjournal.1487201.
ISNAD
Topdağı, Ömer - Güler, Mustafa Can - Eraslan, Ersen - Ekinci Akdemir, Fazile Nur - Tanyeli, Ayhan - Özbek Şebin, Saime - Şebin, Engin. “Can Apigenin Be an Effective Therapeutic Agent Against Experimental Renal Ischemia-Reperfusion Injury?”. Pediatric Practice and Research 12/2 (July 1, 2024): 53-56. https://doi.org/10.21765/pprjournal.1487201.
JAMA
1.Topdağı Ö, Güler MC, Eraslan E, Ekinci Akdemir FN, Tanyeli A, Özbek Şebin S, Şebin E. Can Apigenin Be an Effective Therapeutic Agent Against Experimental Renal Ischemia-Reperfusion Injury? pediatr pract res. 2024;12:53–56.
MLA
Topdağı, Ömer, et al. “Can Apigenin Be an Effective Therapeutic Agent Against Experimental Renal Ischemia-Reperfusion Injury?”. Pediatric Practice and Research, vol. 12, no. 2, July 2024, pp. 53-56, doi:10.21765/pprjournal.1487201.
Vancouver
1.Ömer Topdağı, Mustafa Can Güler, Ersen Eraslan, Fazile Nur Ekinci Akdemir, Ayhan Tanyeli, Saime Özbek Şebin, Engin Şebin. Can Apigenin Be an Effective Therapeutic Agent Against Experimental Renal Ischemia-Reperfusion Injury? pediatr pract res. 2024 Jul. 1;12(2):53-6. doi:10.21765/pprjournal.1487201